CALGARY, Alberta — XORTX Therapeutics Inc. has announced its intention to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its gout treatment program, known as XRx-026. The submission is anticipated to occur in the fourth quarter of 2026, which represents a significant milestone in the company’s regulatory pathway toward a New Drug Application (NDA) filing.
The XRx-026 program is part of the company's broader strategy to develop innovative therapies addressing serious conditions. The U.S. market for gout treatments is estimated to exceed USD$700 million, indicating a substantial financial opportunity for XORTX if the drug gains FDA approval and is successfully marketed.
XORTX Therapeutics is focused on bringing new treatment options to patients suffering from gout and similar conditions, demonstrating a commitment to advancing healthcare solutions. The regulatory process entails a rigorous review and approval pathway, ensuring that the drug meets safety and efficacy standards set by the FDA. As XORTX works toward this goal, stakeholders in the pharmaceutical industry and potential investors are paying close attention to the company’s progress.
Analyzed Canadian Outlets (1)
1 headline